HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Microbiological testing for antiplaque ingredients recommended by FDA Plaque Subcmte..

This article was originally published in The Rose Sheet

Executive Summary

MICROBIOLOGICAL TESTING FOR ANTIPLAQUE INGREDIENTS would be required as part of a company's safety data submission to FDA under a recommendation from the agency's OTC Plaque Subcommittee. In changes made to a "points to consider" document on how to determine safety and effectiveness of antiplaque products, the subcommittee said it is concerned with "the potential of antiplaque ingredients with antimicrobial effects to induce resistance in oral microorganisms or allow an oral overgrowth of inherently resistant potential pathogens."

Latest Headlines
See All
UsernamePublicRestriction

Register

RS001524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel